# ATOMOM KOREA

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/atomom-korea

- Industry: Healthcare IT
- Headquarters: Seoul, South Korea
- Website: www.atomom.kr
- Latest round: Seed (Aug 1, 2022)
- Investors on record: 2

## About

Based in Seoul, South Korea, and founded in 2018 by its CEO, Kwon Tae-wan, Atomam Korea Co., Ltd., trading as Atomom, operates as an artificial intelligence-based self-diagnosis solution for the treatment of atopic diseases. In January 2022, ATOMOM KOREA raised an undisclosed amount in seed funding from new investor New Paradigm Investment. As of 2021, the company's application is installed by more than 100 people. 

The Atomam Korea Co., Ltd. platform provides personalized data-based information for the care of children with atopic dermatitis through a deep learning-based atopic lesion analysis tool used in analyzing the improvement of atopic dermatitis by identifying symptom types and severity. The Atomam platform application enables you to record a child's diet, check and manage changes in a child's atopic symptoms, and find the substances that cause atopy. The application is supported on IOS as well as Android devices.

Atomam Korea Co., Ltd. plans to use the seed funding to advance its Atomam platform application and also to introduce an upgraded model of pediatric healthcare service through various technological cooperation.

## Funding rounds

- Seed, Aug 1, 2022 — Korea Tech Incubator for Startup, New Paradigm Investment
- Seed, Jan 4, 2022 — New Paradigm Investment

## Investors

- New Paradigm Investment (https://capitalatlas.ai/funds/new-paradigm-investment) — Seed
- Korea Tech Incubator for Startup — Seed